key: cord-0838568-sbo61i6p
authors: Fiala, M. J.
title: Ultrasound in COVID-19: a timeline of ultrasound findings in relation to CT
date: 2020-04-18
journal: Clin Radiol
DOI: 10.1016/j.crad.2020.04.003
sha: 402892418e3d7b460c54fab36a21f64be71f4a8f
doc_id: 838568
cord_uid: sbo61i6p

nan

Ultrasound in COVID-19: a timeline of ultrasound findings in relation to CT

SirdThe novel coronavirus (Sars-Cov-2) produces a mild to severe lower respiratory tract infection that is commonly identified by imaging in affected patients, in some cases even before symptom development. 1 Computed tomography (CT) has been the primary imaging method evaluated to date and is often being recommended as a screening tool for patients suspected of having COVID-19. 2 Lung ultrasound is an alternative imaging method with emerging evidence that supports its ability to identify characteristic lesions seen in COVID-19 that are highly consistent with CT imaging, 3,4 without many of the downsides. For clinicians wishing to use ultrasound in the management of patients with COVID-19, it is important to understand the characteristic findings and the timeline in which they would occur. These are described below in comparison to CT.

It is estimated that lung abnormalities present early in the course of disease with bilateral, basal, and peripheral involvement in approximately 50e75% of patients 5, 6 and occur in identifiable stages. Using CT, Jin et al. described five temporal stages of the disease in the lungs as ultra-early (asymptomatic, 1e2 weeks after exposure), early (1e3 days from symptom presentation), rapid progression (3e7 days from symptomatic presentation), consolidation (7e14 days from symptom presentation), and dissipation (2e3 weeks after symptom onset), each occurring with associated CT findings. 1 Similar categories were described by Pan et al. with the exception of a pre-symptomatic phase. 7 CT findings begin as single or multifocal ground-glass opacities, pulmonary nodules, or air bronchograms, which progress with development of interlobular septal thickening and crazy paving, before regression in both size and density at the end of the second week of infection. Opacities often have extensive distribution, typically bilaterally, but also seen unilaterally, with occasional round morphology or reversed-halo or atoll sign. 5 In the dissipation phase, there may be continued patchy consolidative opacities in addition to reticular "strip-like" opacities, bronchial wall thickening, and interlobular septal thickening. 1, 8 The characteristic ultrasound findings (bilateral and multilobar B-lines, subpleural consolidates, irregular pleural line, and decreased blood flow 3, 4, 9 ) have been shown to be highly consistent with CT findings 3,4 and can be expected to develop over a similar timeline. During the first few days of symptom presentation, scattered unilateral or bilateral multilobar B-lines can be visualised. 3, 9 As the disease progresses from the end of week 1 through week 2, development of alveolar interstitial syndrome with diffuse, bilateral B-lines can occur in addition to an irregular pleural line with punctate defects and formation of subpleural consolidations with visible air bronchograms. Lastly, after the end of week 2 during convalescence, there can be an expected regression of prior findings with re-emergence of A-lines. 9 A summary of findings is listed in Table 1 .

Although the literature remains limited, there is still a clear benefit for clinicians to be familiar with ultrasound findings and their progression in COVID-19 patients. It may be particularly useful in helping emergency personnel to triage and diagnose suspected patients, 4 but also for monitoring progression of the disease throughout hospitalisation. Additionally, it offers substantial benefits in comparison to CT imaging, including portability, lower cost, reduced radiation, and ease of sterilisation. Physicians are Table 1 Timeline of common findings of COVID-19 in computed tomography (CT) and ultrasound. 1 

The author declares no conflict of interest.

Zhongnan hospital of Wuhan university novel coronavirus management and research team; evidence-based medicine chapter of China international exchange and promotive association for medical and health care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Diagnosis and treatment of novel coronavirus pneumonia (trial, the fifth version

A preliminary study on the ultrasonic manifestations of peripulmonary lesions of non-critical novel coronavirus pneumonia (COVID-19)

Can lung US help critical care clinicians in the early diagnosis of novel coronavirus (COVID-19) pneumonia?

Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection

Essentials for radiologists on COVID-19: an updatedradiology scientific expert panel

Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia

Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients

Findings of lung ultrasonography of novel corona virus pneumonia during the 2019e2020 epidemic